专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003035695A3 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
公开(公告)号：WO2003035695A3
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/28
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.

2. 发明申请

WO2003035695A2 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
标题翻译：激活或抑制类似感受器的药剂9
公开(公告)号：WO2003035695A2
公开(公告)日：2003-05-01
申请号：PCT/US2002/023645
申请日：2002-07-25
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/55516 , A61K2039/55561
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255 Cys-Arg-Arg 2 58 Cys (as CRRC) or at 265 Cys-Met-GIu 2 68 Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.
摘要翻译：本发明包括与TLR9上的肽段结合并模拟CpG基序的作用的分子。 CpG模拟剂包括但不限于抗体，小分子化合物，肽，肽模拟物和核酸，包括组合物，其包含结合TLR9上的肽段的分子，并模拟适合于给予需要治疗的患者，任选地与例如赋形剂，稀释剂或载体组合。此外，本发明包括在255Cys-Arg-Arg 258Cys作为CRRC或作为CMEC的265Cys-Met-Glu 268Cys与TLR9的CXXC基序结合的那些分子。本发明包括通过诱导Th1型应答来调节免疫应答的方法，包括施用结合TLR9并模拟CpG功能的分子。这些分子也将宿主细胞反应从Th2型反应转移到Th1型反应。因此，施用结合TLR9的本发明的分子可以避免Th2介导的免疫诱导的过敏反应的风险，使得该方法可用于免疫治疗和哮喘治疗。本发明的分子可以与特定的变应原组合施用。

3. 发明申请

WO2002102320A3 FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA 审中-公开
公开(公告)号：WO2002102320A3
公开(公告)日：2002-12-27
申请号：PCT/US2002/019448
申请日：2002-06-14
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C12N15/00
摘要： The present invention includes Fcε fragments conjugated with FCγ fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ ; FCε2-Fcε3- Fcγ; FCε3-Fcγ; and FCε3-Fcε4-FCγ , or any derivative or peptide, which has equivalent immunological function. The Fcγ fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.

4. 发明申请

WO2002102320A2 FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA 审中-公开
标题翻译： FCE融合蛋白治疗过敏和哮喘
公开(公告)号：WO2002102320A2
公开(公告)日：2002-12-27
申请号：PCT/US2002/019448
申请日：2002-06-14
申请人： TANOX, INC. , AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： A61K
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2319/00
摘要： The present invention includes Fcε fragments conjugated with FCγ fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ ; FCε2-Fcε3- Fcγ; FCε3-Fcγ; and FCε3-Fcε4-FCγ , or any derivative or peptide, which has equivalent immunological function. The Fcγ fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.
摘要翻译：本发明包括与FCγ片段缀合的Fcε片段，例如Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; 铰链FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCγ; FC epsilon 2-Fcε3-Fcγ; FC epsilon 3-Fcγ; 和FCε3-Fcε4-FCγ或具有相同免疫功能的任何衍生物或肽。 Fcγ片段可以是IgG亚类（IgG1I IgG2，IgG3或IgG4），优选IgG1或IgG3中任一种的片段，其中片段结合FcyRIIB。本发明还包括适用于在包含例如赋形剂，稀释剂或载体的药物组合物中给患有包含融合蛋白构建体的过敏性疾病患者施用的组合物。该治疗可以与抗IgE治疗或变应原免疫治疗组合。

5. 发明申请

WO2007001422A3 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007001422A3
公开(公告)日：2007-01-04
申请号：PCT/US2005/037734
申请日：2005-10-21
申请人： MEDIMMUNE, INC. , WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
发明人： WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
IPC分类号： A61K39/395 , G01N33/53
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

6. 发明公开

EP1478748A2 FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA 审中-公开
标题翻译： FCE-融合蛋白过敏和哮喘的治疗
公开(公告)号：EP1478748A2
公开(公告)日：2004-11-24
申请号：EP02744451.2
申请日：2002-06-14
申请人： Tanox, Inc.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C12N15/00
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2319/00
摘要： The present invention includes Fcε fragments conjugated with FCη fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCη ; FCε2-Fcε3- Fcη; FCε3-Fcη; and FCε3-Fcε4-FCη , or any derivative or peptide, which has equivalent immunological function. The Fcη fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.

7. 发明公开

EP1412390A2 AGENTS THAT ACTIVATE OR INHIBIT TOLL-LIKE RECEPTOR 9 审中-公开
标题翻译：即意味着最终TLR9激活或抑制
公开(公告)号：EP1412390A2
公开(公告)日：2004-04-28
申请号：EP02795487.4
申请日：2002-07-25
申请人： Tanox, Inc.
发明人： AN, Ling-Ling , WU, Herren , FUNG, Michael, S., C.
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , A61K2039/55516 , A61K2039/55561
摘要： The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255Cys-Arg-Arg 258Cys (as CRRC) or at 265Cys-Met-GIu 268Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式